Analysts Set Gossamer Bio, Inc. (NASDAQ:GOSS) PT at $8.50

Key Points

• Gossamer Bio, Inc. has received a consensus rating of "Buy" from four research firms, with an average one-year target price of $8.50.
• The company reported a quarterly revenue of $11.49 million, significantly exceeding analyst estimates of $4.12 million, alongside an EPS of ($0.17).
• Institutional investors hold 81.23% of Gossamer Bio's stock, indicating strong institutional interest in the company.

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) have been assigned an average recommendation of "Buy" from the five research firms that are covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $8.50.

Several research firms have weighed in on GOSS. Cantor Fitzgerald reissued an "overweight" rating on shares of Gossamer Bio in a research note on Thursday. Wall Street Zen upgraded shares of Gossamer Bio from a "sell" rating to a "hold" rating in a report on Saturday. Wedbush upped their target price on shares of Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 6th. Finally, Scotiabank started coverage on shares of Gossamer Bio in a research note on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 target price on the stock.

Gossamer Bio Stock Performance

Shares of GOSS stock remained flat at $3.46 during trading hours on Wednesday. 4,236,835 shares of the stock traded hands, compared to its average volume of 4,078,129. The company's 50-day moving average price is $2.08 and its two-hundred day moving average price is $1.46. The company has a debt-to-equity ratio of 6.70, a current ratio of 4.40 and a quick ratio of 4.40. Gossamer Bio has a 12 month low of $0.66 and a 12 month high of $3.60. The firm has a market cap of $786.74 million, a PE ratio of -5.58 and a beta of 1.95.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The business had revenue of $11.49 million during the quarter, compared to analyst estimates of $4.12 million. Sell-side analysts anticipate that Gossamer Bio will post -0.28 EPS for the current year.

Institutional Trading of Gossamer Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Investments LP grew its stake in shares of Gossamer Bio by 41.3% in the 4th quarter. Two Sigma Investments LP now owns 891,279 shares of the company's stock worth $806,000 after buying an additional 260,318 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Gossamer Bio during the 1st quarter valued at about $387,000. Two Sigma Advisers LP increased its position in Gossamer Bio by 44.7% during the 4th quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company's stock valued at $1,047,000 after purchasing an additional 357,500 shares during the period. Octagon Capital Advisors LP grew its position in shares of Gossamer Bio by 99.7% in the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company's stock worth $16,599,000 after buying an additional 9,162,117 shares during the last quarter. Finally, Mackenzie Financial Corp grew its position in shares of Gossamer Bio by 499.0% in the 4th quarter. Mackenzie Financial Corp now owns 299,815 shares of the company's stock worth $271,000 after buying an additional 249,765 shares during the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.